Continued tucatinib treatment study
Treatments studied
Part of Cancer, Digestive system, Women’s health & pregnancy clinical trials.
This study lets people who are already benefiting from the cancer drug tucatinib keep taking it after their original study ends. It aims to provide continued access to the treatment while monitoring safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking tucatinib as part of another study and it is helping you without the cancer getting worse.
- You agree to follow the study's reproductive and birth control requirements.
- You are willing and able to attend all scheduled visits and follow the study plan.
- You can give informed consent to participate.
- You are not taking any medications that are not allowed, and you are willing to use any required medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, RO7771950, against another drug called tucatinib. Both are given with standard chemotherapy to see which works better for advanced breast cancer that is HER2-positive. People with brain metastases may join.
This Phase 2 trial studies tucatinib combined with oral etoposide and trastuzumab in people with metastatic HER2-positive breast cancer, aiming to slow cancer growth. You may be eligible if you previously had progression on a similar HER2-targeted treatment or cannot take capecitabine for medical reasons.
This study lets people who were in an earlier Exelixis cancer treatment trial continue receiving the same treatment if it's still helping them. It's designed to see how safe and effective the treatment is over a longer period.
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
This study watches how well a three-drug combination (tucatinib, capecitabine, and trastuzumab) works for women with breast cancer that has spread to other parts of the body and has a protein called HER2. You'll be treated as you normally would be in a clinic, and researchers will track how you respond.
This trial lets people who are already taking the study drug tinengotinib in another study keep getting it for as long as it helps them. It's for those who haven't stopped the drug and are still seeing benefits.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.